SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLZR:a potential 10 bagger?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bob Davis who wrote (65)7/30/1998 9:43:00 AM
From: Bob Davis  Read Replies (2) of 315
 
Last night CLZR released its fourth quarter results, which were a lot
stronger than I expected. In fact, to be blunt about it, they are
spectacular.

"A 25% increase in fourth fiscal quarter revenue - to $12,063,000 this
year from $9,671,000 in 1997 -- enabled Candela Corporation (Nasdaq:CLZR)to post net income of $1.0 million, or 19 cents per share, for the three month period ended June 27, 1998. During the comparable quarter one year ago, Candela's lost $1,310,000, for a net loss per share of 24 cents." The press release is at biz.yahoo.com

After reviewing my database for the Company, it is clear that this is the Company's best quarter on record. Both revenues and earnings per share easily exceed previous levels.

What drove this success? The press release indicates that sales of the Company's new GentleLASE(TM) product line were a major contributor to these financial results. The release also states that the Company's
backlog for this equipment is "now growing dramatically".

As I obtain it, I will post additional information on the Napeague web
site, at napeague.com .

Bob Davis
The Napeague Letter
napeague.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext